Catalog No.
RMC10001
Species reactivity
Mouse
Host species
Rat
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
Antigen NY-CO-13, Cellular tumor antigen p53, P53, Tumor suppressor p53, TP53, Phosphoprotein p53
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P02340
Applications
ELISA, IF, IHC, IP, RIA, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
PAb242
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma., PMID:40516820
The Intrabody Against Murine Double Minute 2 via a p53-Dependent Pathway Induces Apoptosis of Cancer Cell., PMID:40508092
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies., PMID:40497952
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331
Focal High-Grade Areas with a Tumor-in-Tumor Pattern: Another Feature of Pediatric DICER1-Associated Thyroid Carcinoma?, PMID:40448797
Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1-Mutated Metastatic Lung Adenocarcinoma., PMID:40448514
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies., PMID:40435909
Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001
Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma., PMID:40403397
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer., PMID:40393272
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia., PMID:40382198
Molecular and clinicopathological characteristics of invasive breast cancers with HER2-ultralow expression., PMID:40379141
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era., PMID:40361510
FRα expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates., PMID:40344965
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919
PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer., PMID:40273724
Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer., PMID:40239138
Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine., PMID:40237885
Bioconjugates of photon-upconversion nanoparticles with antibodies for the detection of prostate-specific antigen and p53 in heterogeneous and homogeneous immunoassays., PMID:40231544
Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma., PMID:40215977
Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma., PMID:40204067
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272
Pancreatic Cancer: Pathogenesis and Clinical Studies., PMID:40182139
GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms., PMID:40168773
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580
[Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma]., PMID:40159024
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer., PMID:40148708
Mantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond., PMID:40146175
Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review., PMID:40127387
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment., PMID:40111422
Fc fragment of IgG binding protein suppresses tumor growth by stabilizing wild type P53 in colorectal cancer cells., PMID:40108539
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges., PMID:40105906
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes., PMID:40080442
Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy., PMID:40066747
Case Report: Complete response to four cycles of camrelizumab in a PD-L1 negative patient with advanced oral squamous cancer., PMID:40066447
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies., PMID:40045912
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies., PMID:40038334
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)., PMID:40036771
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma., PMID:40030008
Gastric-type endocervical adenocarcinoma, superficial myofibroblastoma, sex cord-stromal tumors, and HSIL in Peutz-Jeghers syndrome: a rare case report, genetic characterization, and review of literature., PMID:40018404
Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents., PMID:40011029
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study., PMID:40009500
An Anti-CD147 Antibody-Drug Conjugate Mehozumab-DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey., PMID:39985225
miRNome analysis reveals mir-155-5p as a protective factor to dengue infection in a resistant Thai cohort., PMID:39976655
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia., PMID:39976417
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia., PMID:39955432
Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma., PMID:39939142
For research use only. Not for human or drug use.
